ARGERON NEPHROTEST LAUNCHED AT THE NATIONAL CONGRESS OF NEPHROLOGY

Argeron Medical Research Industry. ve Tic. Inc. The 38th National Nephrology Congress and the 31st National Nephrology Nursing Congress, which we attended for the first time by opening a stand, were held this year in the Turkish Republic of Northern Cyprus on 13-17 October 2021.

At the National Nephrology Congress, our R&D Director Prof. Argeron NephroTesT, which is the first local biomarker of our country and provides early detection of acute kidney injury, was also introduced by Dr Abdullah Olgun.

Our product, which is a first in the world and enables early detection of damage in the asymptomatic stage before permanent damage occurs in the kidney, has thus brought a solution to the need for new biomarkers, which is one of the main topics of the congress.

Due to the inadequacy of biomarkers such as urea and creatinine, which are present and increase in the symptomatic phase after the damage progresses, in making preventive decisions, our product has received great attention in the congress.

Argeron NephroTesT is now used by many private hospitals and laboratories; It will also play a very important role in reducing the increasing kidney failure in our country.

Argeron Medical Research Industry. ve Tic. Inc. Bülent BIDI, Chairman of the Board of Directors, also stated that all academicians who want to conduct scientific research at the fair will make a test donation if they apply.

Argeron-NephroTesT® (Kidney damage early detection solution) is a solution for measurement of trehalase activity in urine and can be used with urine glucose measurement kits in the field of in vitro diagnostic (biochemical medical diagnosis) to measure urinary trehalase enzyme activity as an indicator of kidney damage. For more detailed information, you can visit www.nephrotest.com